EXACT Sciences Co. (EXAS) SVP D Scott Coward Sells 1,665 Shares

EXACT Sciences Co. (NASDAQ:EXAS) SVP D Scott Coward sold 1,665 shares of the firm’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $52.54, for a total transaction of $87,479.10. Following the completion of the sale, the senior vice president now owns 37,558 shares of the company’s stock, valued at approximately $1,973,297.32. The transaction was disclosed in a document filed with the SEC, which is available at this link.

EXACT Sciences Co. (NASDAQ EXAS) traded down $2.44 during trading hours on Friday, hitting $52.62. 6,362,398 shares of the company’s stock traded hands, compared to its average volume of 1,960,000. EXACT Sciences Co. has a 12-month low of $16.95 and a 12-month high of $63.60. The firm has a market capitalization of $6,300.00, a P/E ratio of -45.76 and a beta of 0.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.98 and a current ratio of 10.34.

EXACT Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Monday, October 30th. The medical research company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. EXACT Sciences had a negative net margin of 60.71% and a negative return on equity of 30.32%. The business had revenue of $72.60 million for the quarter, compared to the consensus estimate of $65.03 million. During the same period in the prior year, the company posted ($0.36) earnings per share. EXACT Sciences’s revenue was up 158.4% compared to the same quarter last year. equities research analysts expect that EXACT Sciences Co. will post -1.09 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Crow Point Partners LLC acquired a new position in shares of EXACT Sciences in the fourth quarter valued at about $145,000. Public Employees Retirement System of Ohio lifted its position in EXACT Sciences by 69.7% during the third quarter. Public Employees Retirement System of Ohio now owns 122,201 shares of the medical research company’s stock worth $5,758,000 after purchasing an additional 50,185 shares during the period. Piedmont Investment Advisors LLC bought a new stake in EXACT Sciences during the third quarter worth about $514,000. California Public Employees Retirement System lifted its position in EXACT Sciences by 2.8% during the third quarter. California Public Employees Retirement System now owns 190,338 shares of the medical research company’s stock worth $8,969,000 after purchasing an additional 5,238 shares during the period. Finally, Ladenburg Thalmann Financial Services Inc. lifted its position in EXACT Sciences by 117.9% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,730 shares of the medical research company’s stock worth $327,000 after purchasing an additional 3,642 shares during the period. Institutional investors and hedge funds own 82.39% of the company’s stock.

A number of brokerages recently issued reports on EXAS. Leerink Swann restated an “outperform” rating and set a $50.00 price objective (up previously from $45.00) on shares of EXACT Sciences in a report on Thursday, September 21st. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, December 21st. William Blair reaffirmed a “buy” rating on shares of EXACT Sciences in a research note on Wednesday. Canaccord Genuity reissued a “buy” rating and issued a $60.00 price objective (up previously from $45.00) on shares of EXACT Sciences in a research report on Tuesday, October 3rd. Finally, Zacks Investment Research raised shares of EXACT Sciences from a “hold” rating to a “buy” rating and set a $51.00 price objective on the stock in a research report on Tuesday, September 26th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $50.58.

TRADEMARK VIOLATION NOTICE: “EXACT Sciences Co. (EXAS) SVP D Scott Coward Sells 1,665 Shares” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/13/d-scott-coward-sells-1665-shares-of-exact-sciences-co-exas-stock.html.

About EXACT Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply